Last 7 days
3.2%
Last 30 days
1.4%
Last 90 days
-19.2%
Trailing 12 Months
-15.5%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 51.3M | 51.3M | 54.5M | 57.4M |
2022 | 54.3M | 52.4M | 52.0M | 51.3M |
2021 | 66.3M | 64.2M | 59.1M | 55.3M |
2020 | 87.9M | 76.8M | 82.6M | 71.9M |
2019 | 57.4M | 60.1M | 59.7M | 73.4M |
2018 | 20.6M | 40.6M | 49.1M | 60.4M |
2017 | 33.3M | 31.4M | 16.6M | 15.4M |
2016 | 40.1M | 38.5M | 46.8M | 48.6M |
2015 | 31.1M | 35.3M | 39.7M | 42.1M |
2014 | 1.1M | 4.1M | 10.4M | 11.7M |
2013 | 104.3M | 78.5M | 52.7M | 26.9M |
2012 | 0 | 0 | 0 | 130.1M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 15, 2024 | winningham rick e | acquired | 23,362 | 8.64 | 2,704 | chief executive officer |
Mar 15, 2024 | winningham rick e | gifted | - | - | 3,900 | chief executive officer |
Mar 15, 2024 | winningham rick e | gifted | - | - | -10,900 | chief executive officer |
Feb 22, 2024 | farnum rhonda | sold | -10,922 | 8.71 | -1,254 | svp, comm & medical affairs |
Feb 20, 2024 | sawaf aziz | sold (taxes) | -151,961 | 8.92 | -17,036 | svp & chief financial officer |
Feb 20, 2024 | graham richard a | sold (taxes) | -172,102 | 8.92 | -19,294 | svp, research & development |
Feb 20, 2024 | farnum rhonda | sold (taxes) | -162,513 | 8.92 | -18,219 | svp, comm & medical affairs |
Feb 20, 2024 | miller aine | sold (taxes) | -105,095 | 8.92 | -11,782 | svp, dev & head of ire office |
Feb 20, 2024 | grimaud brett a. | sold (taxes) | -156,947 | 8.92 | -17,595 | svp, gen counsel and secretary |
Feb 20, 2024 | winningham rick e | sold (taxes) | -331,788 | 8.92 | -37,196 | chief executive officer |
Which funds bought or sold TBPH recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | reduced | -2.08 | 343 | 1,585 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | reduced | -9.12 | 6,085,900 | 39,219,300 | -% |
Mar 05, 2024 | GERBER, LLC | new | - | 112,400 | 112,400 | 0.10% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 112 | 4,107,580 | 6,435,820 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -8.99 | 45,008 | 287,856 | -% |
Feb 20, 2024 | Pacific Center for Financial Services | unchanged | - | 149 | 641 | -% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | reduced | -4.33 | 102,000 | 517,000 | -% |
Feb 16, 2024 | Madison Avenue Partners, LP | unchanged | - | 18,301,900 | 78,817,400 | 11.13% |
Feb 16, 2024 | GSA CAPITAL PARTNERS LLP | reduced | -76.36 | -1,947,000 | 866,000 | 0.07% |
Feb 15, 2024 | Legal & General Group Plc | reduced | -9.00 | 88,490 | 566,429 | -% |
Unveiling Theravance Biopharma Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Theravance Biopharma Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 42.3B | 6.8B | -8.96 | 6.17 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 19.4B | 1.8B | -44.17 | 10.64 | ||||
BMRN | 16.7B | 2.4B | 99.73 | 6.91 | ||||
INCY | 12.8B | 3.7B | 21.46 | 3.47 | ||||
MID-CAP | ||||||||
APLS | 7.1B | 396.6M | -13.34 | 17.78 | ||||
BBIO | 5.4B | - | -8.31 | 60.35 | ||||
AXSM | 3.8B | 270.6M | -15.68 | 13.86 | ||||
ARWR | 3.6B | 240.7M | -11.98 | 14.77 | ||||
ACAD | 3.0B | 726.4M | -48.93 | 4.13 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 398.2M | 26.85 | 4.82 | ||||
NVAX | 678.8M | 983.7M | -1.25 | 0.69 | ||||
CRBP | 373.2M | 881.7K | -8.37 | 466.16 | ||||
INO | 304.5M | 4.9M | -2.25 | 62.57 | ||||
IBIO | 11.8M | 2.1M | -0.43 | 2.14 |
Theravance Biopharma Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | 11.9% | 17,565,000 | 15,693,000 | 13,749,000 | 10,417,000 | 14,649,000 | 12,451,000 | 11,750,500 | 11,050,000 | 13,196,000 | 14,946,000 | 13,194,000 | 12,914,000 | 14,257,000 | 18,730,000 | 18,257,000 | 15,008,000 | 19,862,000 | 29,499,000 | 12,427,000 | 26,150,000 | 5,338,000 |
Operating Expenses | -2.6% | 23,805,000 | 24,453,000 | 29,872,000 | 35,329,000 | 32,081,000 | 26,653,000 | - | 34,151,000 | 50,419,000 | 71,113,000 | 66,809,000 | 77,024,000 | 98,149,000 | 95,220,000 | 94,872,000 | 87,184,000 | 92,338,000 | 100,071,000 | 77,628,000 | 68,626,000 | 79,004,000 |
S&GA Expenses | -4.0% | 15,492,000 | 16,142,000 | 19,278,000 | 19,183,000 | 16,732,000 | 16,277,000 | - | 16,222,000 | 17,842,000 | 21,516,000 | 21,299,000 | 25,931,000 | 30,550,000 | 29,925,000 | 27,501,000 | 24,780,000 | 26,325,000 | 33,046,000 | 25,622,000 | 22,227,000 | 25,186,000 |
R&D Expenses | 0.0% | 8,313,000 | 8,311,000 | 9,425,000 | 14,572,000 | 15,348,000 | 9,867,000 | - | 14,924,000 | 23,253,000 | 31,226,000 | 43,739,000 | 51,093,000 | 67,599,000 | 65,165,000 | 67,371,000 | 62,404,000 | 66,013,000 | 67,025,000 | 52,006,000 | 46,399,000 | 53,818,000 |
EBITDA Margin | 20.8% | -0.82 | -1.03 | -1.18 | -1.31 | -1.62 | -2.79 | -3.53 | -3.51 | -3.76 | -4.23 | -4.52 | -4.29 | -4.32 | - | - | - | - | - | - | - | - |
Interest Expenses | 2.3% | 623,000 | 609,000 | 568,000 | 550,000 | 550,000 | 1,545,000 | - | 2,137,000 | 2,137,000 | -7,468,500 | 2,136,000 | 11,612,000 | 11,873,000 | -24,358,000 | 11,573,000 | 11,391,000 | 9,941,000 | 8,035,000 | 8,068,000 | 7,901,000 | 7,858,000 |
Income Taxes | 155.2% | 3,488,000 | 1,367,000 | 1,500,000 | -395,000 | -3,000 | -507,000 | - | -5,000 | 524,000 | 1,756,000 | -7,000 | -220,000 | 227,000 | -8,799,000 | 93,000 | 39,000 | 147,000 | 49,000 | -5,552,000 | 201,000 | 80,000 |
Earnings Before Taxes | 33.9% | -5,016,000 | -7,583,000 | -14,187,000 | -22,483,000 | -14,259,000 | -16,023,000 | - | -22,798,000 | -39,735,000 | -67,597,000 | -55,917,000 | -52,625,000 | -79,452,000 | -84,039,000 | -73,550,000 | -62,848,000 | -82,906,000 | -65,557,000 | -63,983,000 | -39,637,000 | -72,500,000 |
EBT Margin | 20.1% | -0.86 | -1.07 | -1.31 | -1.47 | -1.81 | -2.83 | -3.58 | -3.55 | -3.98 | -4.62 | -4.60 | -4.51 | -4.53 | - | - | - | - | - | - | - | - |
Net Income | 4.9% | -8,510,000 | -8,950,000 | -15,645,000 | -22,088,000 | -10,362,000 | 916,631,000 | - | -8,191,000 | -25,946,000 | -32,034,000 | -35,308,000 | -52,405,000 | -79,679,000 | -58,434,000 | -73,643,000 | -62,887,000 | -83,053,000 | -65,606,000 | -58,431,000 | -39,838,000 | -72,580,000 |
Net Income Margin | 8.2% | -0.96 | -1.05 | 16.94 | 17.00 | 16.99 | -1.96 | -1.95 | -1.94 | -2.69 | -3.61 | -3.82 | -4.12 | -4.15 | - | - | - | - | - | - | - | - |
Free Cashflow | 65.6% | -854,000 | -2,486,000 | -13,074,000 | -11,859,000 | -124,693,000 | -22,775,000 | -15,368,000 | -15,368,000 | -26,707,000 | -43,072,000 | -46,084,000 | -50,751,000 | -70,503,000 | - | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -7.6% | 382 | 414 | 447 | 539 | 607 | 763 | 72.00 | 361 | 355 | 375 | 403 | 429 | 375 | 469 | 512 | 564 | 605 | 409 | 445 | 492 | 531 |
Current Assets | -17.4% | 134 | 162 | 192 | 261 | 353 | 512 | - | 155 | 205 | 250 | 297 | 333 | 293 | 393 | 451 | 498 | 534 | 37.00 | 356 | 426 | 467 |
Cash Equivalents | -43.7% | 40.00 | 72.00 | 106 | 188 | 298 | 419 | 29.00 | 87.00 | 94.00 | 91.00 | 121 | 205 | 114 | 81.00 | 93.00 | 105 | 333 | 59.00 | 102 | 178 | 223 |
Net PPE | -2.4% | 9.00 | 9.00 | 10.00 | 12.00 | 12.00 | 12.00 | - | 13.00 | 13.00 | 14.00 | 16.00 | 17.00 | 17.00 | 16.00 | 15.00 | 14.00 | 14.00 | 13.00 | 12.00 | 13.00 | 13.00 |
Current Liabilities | -2.4% | 25.00 | 25.00 | 25.00 | 26.00 | 29.00 | 142 | - | 33.00 | 44.00 | 59.00 | 66.00 | 67.00 | 86.00 | 124 | 104 | 107 | 98.00 | 3.00 | 109 | 110 | 114 |
Shareholder's Equity | -13.5% | 213 | 246 | 280 | 371 | 442 | 481 | - | - | - | -338 | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings | -0.9% | -909 | -900 | -891 | -876 | -853 | -843 | - | -1,760 | -1,751 | -1,726 | -1,694 | -1,658 | -1,606 | -1,526 | -1,468 | -1,394 | -1,331 | -1,248 | -1,182 | -1,124 | -1,084 |
Additional Paid-In Capital | -2.2% | 1,122 | 1,147 | 1,172 | 1,247 | 1,296 | 1,324 | - | 1,410 | 1,401 | 1,387 | 1,370 | 1,358 | 1,233 | 1,223 | 1,207 | 1,192 | 1,173 | 1,025 | 1,000 | 987 | 972 |
Shares Outstanding | -5.4% | 48.00 | 51.00 | 54.00 | 61.00 | 65.00 | 76.00 | 76.00 | 76.00 | 75.00 | 74.00 | 68.00 | 66.00 | 64.00 | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | - | 677 | - | - | - | 882 | - | - | - | 1,280 | - | - | - | 893 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | 65.6% | -0.85 | -2.49 | -12.44 | -11.22 | -124 | -22.14 | -14.73 | -26.07 | -42.43 | -45.45 | -50.11 | -69.86 | -64.92 | -77.03 | -53.35 | -55.10 | -64.35 | -44.62 | -48.03 | -81.19 | -52.18 |
Share Based Compensation | -7.0% | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 9.00 | 10.00 | 15.00 | 17.00 | 14.00 | 15.00 | 16.00 | 16.00 | 16.00 | 17.00 | 15.00 | 24.00 | 13.00 | 11.00 | 12.00 | 12.00 |
Cashflow From Investing | -3123.8% | -0.68 | -0.02 | 11.00 | -43.05 | 39.00 | 1,075 | 8.00 | 32.00 | 11.00 | -35.79 | 36.00 | 114 | 52.00 | 67.00 | -176 | 68.00 | 14.00 | -23.66 | -1.30 | -72.16 | 99.00 |
Cashflow From Financing | 2.5% | -30.61 | -31.40 | -80.68 | -56.24 | -35.47 | -722 | 0.00 | -1.45 | 0.00 | -2.29 | 105 | -11.29 | 1.00 | -0.96 | 2.00 | 261 | -1.54 | -0.13 | 4.00 | -1.43 | 230 |
Buy Backs | -2.0% | 30.00 | 31.00 | 81.00 | 55.00 | - | 94.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands | 12 Months Ended | |||||
---|---|---|---|---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |||||
Revenue: | ||||||
Total revenue | $ 57,424,000 | $ 51,346,000 | ||||
Expenses: | ||||||
Research and development | [1] | 40,621,000 | 63,392,000 | |||
Selling, general and administrative | [1] | 70,095,000 | 67,073,000 | |||
Restructuring and related expenses | [1] | 2,743,000 | 12,838,000 | |||
Total expenses | 113,459,000 | 143,303,000 | ||||
Loss from operations | (56,035,000) | (91,957,000) | ||||
Interest expense | [2] | (2,350,000) | (6,369,000) | |||
Loss on extinguishment of debt | (3,034,000) | |||||
Interest income and other income (expense), net | 9,116,000 | 8,545,000 | ||||
Loss from continuing operations before income taxes | (49,269,000) | (92,815,000) | ||||
Provision for income tax expense | (5,924,000) | (9,000) | ||||
Net loss from continuing operations | (55,193,000) | (92,824,000) | ||||
Income from discontinued operations before income taxes | 1,143,930,000 | |||||
Provision for income tax expense | (178,974,000) | |||||
Net income from discontinued operations | 964,956,000 | |||||
Net Income (Loss) | $ (55,193,000) | $ 872,132,000 | ||||
Net income (loss) per share: | ||||||
Continuing operations - basic (in dollars per share) | $ (1.00) | $ (1.26) | ||||
Continuing operations - diluted (in dollars per share) | (1.00) | (1.26) | ||||
Discontinued operations - basic (in dollars per share) | 13.11 | |||||
Discontinued operations - diluted (in dollars per share) | 13.11 | |||||
Net income (loss) - basic (in dollars per share) | (1.00) | 11.85 | ||||
Net income (loss) - diluted (in dollars per share) | $ (1.00) | $ 11.85 | ||||
Shares used to compute net income (loss) per share - basic | 55,303 | 73,591 | ||||
Shares used to compute net income (loss) per share - diluted | 55,303 | 73,591 | ||||
Viatris collaboration agreement | ||||||
Revenue: | ||||||
Total revenue | $ 57,201,000 | $ 48,624,000 | ||||
Viatris royalties (Non-US) | ||||||
Revenue: | ||||||
Total revenue | 7,000 | 30,000 | ||||
Collaboration revenue | ||||||
Revenue: | ||||||
Total revenue | $ 216,000 | 192,000 | ||||
Licensing revenue | ||||||
Revenue: | ||||||
Total revenue | $ 2,500,000 | |||||
|
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 39,545 | $ 298,172 |
Short-term marketable securities | 62,881 | 29,312 |
Receivables from collaborative arrangements | 17,474 | 16,785 |
Prepaid clinical and development services | 2,038 | 1,513 |
Other prepaid and current assets | 11,603 | 7,682 |
Total current assets | 133,541 | 353,464 |
Property and equipment, net | 9,068 | 11,875 |
Operating lease assets | 36,287 | 40,126 |
Future contingent milestone and royalty assets | 194,200 | 194,200 |
Restricted cash | 836 | 836 |
Other assets | 8,067 | 6,899 |
Total assets | 381,999 | 607,400 |
Current liabilities: | ||
Accounts payable | 1,524 | 1,554 |
Accrued personnel-related expenses | 6,443 | 10,314 |
Accrued clinical and development expenses | 2,246 | 4,932 |
Accrued general and administrative expenses | 2,900 | 4,020 |
Operating lease liabilities | 3,923 | 6,753 |
Tenant improvement payable to subleasee | 6,490 | |
Other accrued liabilities | 1,241 | 1,142 |
Total current liabilities | 24,767 | 28,715 |
Long-term operating lease liabilities | 45,236 | 45,407 |
Future royalty payment contingency | 27,788 | 25,438 |
Long-term deferred revenue | 192 | |
Unrecognized tax benefits | 65,294 | 64,191 |
Other long-term liabilities | 5,919 | 1,657 |
Commitments and contingencies | ||
Shareholders' Equity | ||
Preferred shares, $0.00001 par value: 230 shares authorized, no shares issued or outstanding | ||
Ordinary shares, $0.00001 par value: 200,000 shares authorized; 48,091 and 65,227 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively | 1 | |
Additional paid-in capital | 1,122,164 | 1,295,725 |
Accumulated other comprehensive loss | (65) | (15) |
Accumulated deficit | (909,104) | (853,911) |
Total shareholders' equity | 212,995 | 441,800 |
Total liabilities and shareholders' equity | $ 381,999 | $ 607,400 |